SCHEMBL7852863

SCHEMBL7852863

CCOC(=O)C(Cc1ccc(OCC=C2c3cnccc3-c3cccnc32)cc1)OCC

nearest known ligand 0.56

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 17/20 0.56
PPARG P37231 15/20 0.56
PPARD Q03181 11/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7852860 1.00 PPARA (0.56) PPARAPPARGPPARD
SCHEMBL7843860 0.93 PPARG (0.49) PPARAPPARGPPARD
SCHEMBL7843858 0.93 PPARG (0.49) PPARAPPARGPPARD
SCHEMBL7852808 0.92 PPARA (0.68) PPARAPPARGPPARD
SCHEMBL7852809 0.92 PPARA (0.68) PPARAPPARGPPARD
SCHEMBL6735231 0.92 PPARG (0.67) PPARAPPARGPPARD
SCHEMBL6735228 0.92 PPARG (0.67) PPARAPPARGPPARD
SCHEMBL7851899 0.91 PPARG (0.51) PPARAPPARGPPARD
SCHEMBL7851898 0.91 PPARG (0.51) PPARAPPARGPPARD
SCHEMBL7852707 0.91 PPARA (0.61) PPARAPPARGPPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6300339-B1 USEFUL FOR THRERAPY AND/OR PROPHYLAXIS OF INSULIN RESISTANCE (TYPE 2 DIABETES), IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDEMIA, HYPERTENSION, OBESITY, INSULIN RESISTANCE, HYPERGLYCEMIA, ATHEROSCLEROSIS, HYPERLIPIDEMIA, CORONARY ARTERY DISEASE NOVO NORDISK A/S (DK) 2001-10-09 US claimed
EP-1123292-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP claimed
WO-2000023445-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO claimed
US-6300339-B1 USEFUL FOR THRERAPY AND/OR PROPHYLAXIS OF INSULIN RESISTANCE (TYPE 2 DIABETES), IMPAIRED GLUCOSE TOLERANCE, DYSLIPIDEMIA, HYPERTENSION, OBESITY, INSULIN RESISTANCE, HYPERGLYCEMIA, ATHEROSCLEROSIS, HYPERLIPIDEMIA, CORONARY ARTERY DISEASE NOVO NORDISK A/S (DK) 2001-10-09 US disclosed
EP-1123292-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-08-16 EP disclosed
WO-2000023445-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2000-04-27 WO disclosed